Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2011 Oct;50(10):991-1000.
doi: 10.1016/j.jaac.2011.06.008. Epub 2011 Aug 12.

Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis

Michael H Bloch  1 , Ahmad Qawasmi
Affiliations
Meta-Analysis

Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis

Michael H Bloch et al. J Am Acad Child Adolesc Psychiatry. 2011 Oct.

Abstract

Objective: Several studies have demonstrated differences in omega-3 fatty acid composition in plasma and in erythrocyte membranes in patients with attention-deficit/hyperactivity disorder (ADHD) compared with unaffected controls. Omega-3 fatty acids have anti-inflammatory properties and can alter central nervous system cell membrane fluidity and phospholipid composition. Cell membrane fluidity can alter serotonin and dopamine neurotransmission. The goal of this meta-analysis was to examine the efficacy of omega-3 fatty acid supplementation in children with ADHD.

Method: PubMed was searched for randomized placebo-controlled trials examining omega-3 fatty acid supplementation in children with ADHD symptomatology. The primary outcome measurement was standardized mean difference in rating scales of ADHD severity. Secondary analyses were conducted to determine the effects of dosing of different omega-3 fatty acids in supplements.

Results: Ten trials involving 699 children were included in this meta-analysis. Omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms. Eicosapentaenoic acid dose within supplements was significantly correlated with supplement efficacy. No evidence of publication bias or heterogeneity between trials was found.

Conclusion: Omega-3 fatty acid supplementation, particularly with higher doses of eicosapentaenoic acid, was modestly effective in the treatment of ADHD. The relative efficacy of omega-3 fatty acid supplementation was modest compared with currently available pharmacotherapies for ADHD such as psychostimulants, atomoxetine, or α(2) agonists. However, given its relatively benign side-effect profile and evidence of modest efficacy, it may be reasonable to use omega-3 fatty supplementation to augment traditional pharmacologic interventions or for families who decline other psychopharmacologic options.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow Chart Depicting Selection of Studies
Note: ADHD = attention-deficit/hyperactivity disorder.
Figure 2
Figure 2. Omega-3 Fatty Acid Supplementation for Attention-Deficit Hyperactivity Disorder (ADHD)
Note: Forest plot depicting efficacy of omega-3 fatty acid supplementation compared to placebo in the treatment of children with ADHD symptoms. Ten studies involving 699 participants contributed to this analysis. There was a significant benefit of omega-3 supplementation compared to placebo and no evidence of heterogeneity or publication bias. CI = confidence interval.
Figure 3
Figure 3. Eicosapentaenoic acid dose and Efficacy of Omega-3 Fatty Acid Supplementation for Attention-Deficit Hyperactivity Disorder (ADHD)
Note: Scatterplot of measured efficacy of omega-3 fatty acid supplementation in trials as a function of Eicosapentaenoic acid (EPA) dose utilized. Trials were weighted (size of circles) using the generic inverse variance method. Higher doses of EPA within essential fatty acids supplements was significantly associated with increased efficacy in treating ADHD symptoms (β=0.36 (95% CI: 0.01–0.72), t=2.34, p=0.04, R2=0.38). Two trials, Johnson 2008 (effect size=0.35, EPA dose=558mg weight=11.1%) and Richardson 2005 (effect size=0.36, EPA dose=558mg weight=17.3%) had overlapping point estimates on this figure. CI = confidence interval.
See this image and copyright information in PMC

Comment in

References

    1. Diagnostic and statistical manual of mental disorders. 4th ed American Psychiatric Association; 1994.
    1. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics. 2000;105(5):1158–70. - PubMed
    1. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA. 1998;279(14):1100–7. - PubMed
    1. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409–32. - PubMed
    1. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165(11):1475–88. - PMC - PubMed

Publication types

MeSH terms